Slingshot members are tracking this event:

Having used Halozyme Therapuetics' ENHANZE technology ,Roche’s is awaiting June FDA action date on rituximab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
HALO Community voting in process
RHHBY Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 23, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rituximab, Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma, Fda Review, Enhanze